Should Jardiance (empagliflozin) be discontinued when a patient develops balanitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Do Not Discontinue Jardiance for Balanitis - Treat the Infection

Jardiance (empagliflozin) should NOT be discontinued when a patient develops balanitis. Instead, treat the genital infection with topical antifungal agents while continuing the SGLT2 inhibitor, given the significant cardiovascular and renal mortality benefits of this medication 1.

Why Continue Jardiance Despite Balanitis

The FDA label explicitly addresses genital mycotic infections as an expected, manageable adverse effect 1. SGLT2 inhibitors like Jardiance increase the risk for genital mycotic infections, but the label instructs clinicians to "monitor and treat as appropriate"—not to discontinue the medication 1.

This approach prioritizes the substantial mortality and morbidity benefits:

  • 38% reduction in cardiovascular mortality
  • 35% reduction in heart failure hospitalizations
  • 34% reduction in kidney failure risk 2, 3, 4

These life-saving benefits far outweigh the inconvenience of a treatable genital infection.

Management Algorithm for Balanitis on Jardiance

Step 1: Confirm the diagnosis

  • Balanitis presents as erythematous areas on the glans with pruritus or irritation 5, 6, 7
  • Most cases are mild-to-moderate candidal infections 8

Step 2: Treat with topical antifungals

  • Use topical antifungal agents (clotrimazole, miconazole, or similar azoles)
  • CDC guidelines specifically recommend treating male partners with symptomatic balanitis using topical antifungals 5, 6, 7
  • Most infections respond to standard antimicrobial treatment and are mild or moderate 8

Step 3: Continue Jardiance

  • Do NOT discontinue empagliflozin
  • These infections rarely lead to treatment discontinuation 8, 3
  • Discontinuation rates due to genital infections are very low in clinical trials 8

Step 4: Monitor for recurrence

  • If infections become recurrent (≥3-4 episodes), consider prophylactic antifungal strategies
  • Even with recurrent infections, the mortality benefit of continuing Jardiance typically outweighs the nuisance of repeated mild infections

Key Clinical Considerations

Genital infections are expected with SGLT2 inhibitors: The mechanism is straightforward—glucosuria creates a favorable environment for candidal growth 8. This is a pharmacologic consequence, not a reason to abandon a life-saving medication.

The infections are manageable: Analysis of 4,545 patients showed genital infections occurred in 4-6% of dapagliflozin-treated patients versus 0.9% on placebo, but these were "generally mild to moderate, clinically manageable, and rarely led to discontinuation" 8. Similar safety profiles exist for empagliflozin 3, 9.

No dose-response relationship: There's no clear correlation between SGLT2 inhibitor dose and infection risk 8, so dose reduction won't help.

When to Consider Discontinuation (Rare)

Only discontinue Jardiance for genital infections if:

  • Necrotizing fasciitis (Fournier's gangrene) develops - this is a medical emergency requiring immediate discontinuation, broad-spectrum antibiotics, and surgical debridement 1
  • Severe, treatment-refractory recurrent infections that significantly impair quality of life despite optimal antifungal therapy
  • Patient develops hypersensitivity reaction to the medication itself 1

Common Pitfall to Avoid

Do not reflexively discontinue SGLT2 inhibitors for simple balanitis. This is the most common error—clinicians see "genital infection" and immediately stop the drug, thereby removing a medication that reduces cardiovascular death by 38% 2. The FDA label and clinical guidelines are clear: treat the infection, continue the drug 1.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.